Learn How The Microfluidic Technology In OBM rapid A1c, A New At-Home Device For Monitoring HbA1C, Can Generate Lab-Accurate Results From A Single Drop of Blood For More Accessible And Affordable Testing.
Seattle, WA, June 4, 2024 —Orange Biomed—a South Korean diabetes management innovator—just announced today that they will present OBM rapid A1c, a reusable, pocket-sized A1C meter that uses single-cell analysis of red blood cells to overcome the accuracy challenges with traditional POC tests on the market, at the American Diabetes Association’s (ADA’s) 84th Scientific Sessions.

“By seamlessly integrating lab-level technology into point-of-care devices, we are on a mission to make healthcare more accessible and affordable for everyone,” stated Co-Founder Yeaseul Park. OBM rapid A1c is undergoing clinical trials in the U.S. market, with OTC FDA clearance anticipated in early 2025. The meter provides results in <5 minutes and obtains the same level of accuracy as traditional laboratory equipment within a pocket-sized unit.

“We are pleased to have been invited back to present at the ADA’s Scientific Sessions for the second year in a row. Last year, we previewed OBM rapid A1c in the prototype phase. As we get closer to U.S. commercialization, we are inviting select diabetes care professionals to demo our cutting-edge solution before public release.”

Endocrinologists and diabetes care professionals seeking to try the new method of A1C testing first are encouraged to contact Orange Biomed in advance and stop by poster number 727-P on June 22nd, from 12:30 PM – 1:30 PM at West Concourse A4-B2.

About Orange Biomed:

Founded in South Korea, with U.S. headquarters in Seattle, WA, Orange Biomed was founded in 2021 by Duke University alumnus Dr. Unghyeon Ko and Yeaseul Park to solve unmet diabetes-focused healthcare needs. The healthcare startup innovates with cutting-edge diabetes management technology.

In 2024, Orange Biomed acquired an ISO 9001 certification, which certified its quality control capabilities as meeting international standards.

Global studies of OBM rapid A1c have closed with Asan Medical Center and are currently underway in the U.S. market. U.S. FDA clearances of OBM rapid A1c for OTC and Professional usage are anticipated for early 2025. Learn more.

About the American Diabetes Association:

The American Diabetes Association is a United States-based nonprofit that seeks to educate the public about diabetes and to help those affected by it through funding research to manage, cure and prevent diabetes, including type 1 diabetes, type 2 diabetes, gestational diabetes, and pre-diabetes. Learn more.

Media Contact:

Shannon Lindahl